Eduardo Rodríguez-Arbolí

19PUBLICATIONS
118CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursOtorhinolaryngologyCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Jun 30, 2026
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

|May 07, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.

|Apr 22, 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

|Apr 10, 2026
Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Juan M Alonso-Dominguez, Tamara Castaño-Bonilla, Cristina Gil

|Feb 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard

Pageof 4

Frequent Collaborators

10 joint publications

Pau Montesinos

6 joint publications

Juan Miguel Bergua-Burgues

5 joint publications

Lorenzo Algarra-Algarra

5 joint publications

David Martínez-Cuadrón